KR101619733B1 - A composition for anti-tussive activity or discharge of phlegm activity comprising of lonicera japonica, scutellaria baicalensis, adenophorea radix and polygonati odorati - Google Patents
A composition for anti-tussive activity or discharge of phlegm activity comprising of lonicera japonica, scutellaria baicalensis, adenophorea radix and polygonati odorati Download PDFInfo
- Publication number
- KR101619733B1 KR101619733B1 KR1020140140787A KR20140140787A KR101619733B1 KR 101619733 B1 KR101619733 B1 KR 101619733B1 KR 1020140140787 A KR1020140140787 A KR 1020140140787A KR 20140140787 A KR20140140787 A KR 20140140787A KR 101619733 B1 KR101619733 B1 KR 101619733B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- activity
- composition
- gold
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 230000000694 effects Effects 0.000 title description 14
- 244000167230 Lonicera japonica Species 0.000 title description 2
- 235000017617 Lonicera japonica Nutrition 0.000 title description 2
- 240000004534 Scutellaria baicalensis Species 0.000 title description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 title description 2
- 241000253343 Chromadorea Species 0.000 title 1
- 206010062717 Increased upper airway secretion Diseases 0.000 title 1
- 230000000954 anitussive effect Effects 0.000 title 1
- 208000026435 phlegm Diseases 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 30
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229910052737 gold Inorganic materials 0.000 claims abstract description 26
- 239000010931 gold Substances 0.000 claims abstract description 26
- 206010011224 Cough Diseases 0.000 claims abstract description 24
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 22
- 206010036790 Productive cough Diseases 0.000 claims abstract description 19
- 239000010977 jade Substances 0.000 claims abstract description 19
- 208000024794 sputum Diseases 0.000 claims abstract description 19
- 210000003802 sputum Anatomy 0.000 claims abstract description 19
- 239000010453 quartz Substances 0.000 claims abstract description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 230000003578 releasing effect Effects 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 241000208340 Araliaceae Species 0.000 claims abstract description 10
- 208000001840 Dandruff Diseases 0.000 claims abstract description 10
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 10
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 10
- 235000008434 ginseng Nutrition 0.000 claims abstract description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims abstract 3
- 229940072033 potash Drugs 0.000 claims abstract 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims abstract 3
- 235000015320 potassium carbonate Nutrition 0.000 claims abstract 3
- 239000000284 extract Substances 0.000 claims description 48
- 239000004615 ingredient Substances 0.000 claims description 4
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 241000219061 Rheum Species 0.000 claims 2
- 229940112822 chewing gum Drugs 0.000 claims 1
- 235000015218 chewing gum Nutrition 0.000 claims 1
- 238000000605 extraction Methods 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000000469 ethanolic extract Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229960004559 theobromine Drugs 0.000 description 5
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229940097275 indigo Drugs 0.000 description 4
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WCBPJVKVIMMEQC-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine Chemical group [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 WCBPJVKVIMMEQC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 3
- 229960005174 ambroxol Drugs 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 244000184734 Pyrus japonica Species 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000010431 corundum Substances 0.000 description 2
- 229910052593 corundum Inorganic materials 0.000 description 2
- 229910052602 gypsum Inorganic materials 0.000 description 2
- 239000010440 gypsum Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- -1 methylphedrine Chemical compound 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241001633574 Adenophora stricta Species 0.000 description 1
- 241001116477 Adenophora triphylla Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- SXAMSIHRCZWLMU-UHFFFAOYSA-N Convallamarin Natural products CC1OC(OC2C(C)OC(OC3CC(CC4CCC5C(CCC6(C)C5CC7OC(O)(CCC(=C)COC8OC(CO)C(O)C(O)C8O)C(C)C67)C34C)OC9OC(CO)C(OC%10OC(C)C(O)C(O)C%10O)C(O)C9O)C(O)C2O)C(O)C(O)C1O SXAMSIHRCZWLMU-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000245240 Lonicera Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 241000219995 Wisteria Species 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- PSJVJZYSECBFHJ-BANYBNOTSA-N convallamarin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@@H]1O)O)O[C@@H]1C[C@@H](C[C@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@]21C)C)[C@@H]([C@@](O5)(O)CCC(=C)CO[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)C)O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](C)O1)O)[C@@H]1O[C@H](C)[C@H](O)[C@@H](O)[C@H]1O PSJVJZYSECBFHJ-BANYBNOTSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- KUDPGZONDFORKU-UHFFFAOYSA-N n-chloroaniline Chemical compound ClNC1=CC=CC=C1 KUDPGZONDFORKU-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- ZYOCVAPRXVCQQR-UHFFFAOYSA-N taraxasterone Natural products CC12CCC(=O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(=C)CCC3(C)CCC21C ZYOCVAPRXVCQQR-UHFFFAOYSA-N 0.000 description 1
- DBCAVZSSFGIHQZ-YLAYQGCQSA-N taraxerone Chemical compound CC([C@@H]1CC2)(C)C(=O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 DBCAVZSSFGIHQZ-YLAYQGCQSA-N 0.000 description 1
- FXOCQCYCKZXBIJ-UHFFFAOYSA-N taraxerone Natural products CC1C=C2C(C)(CCC3C4(C)CCC(=O)C(C)(C)C4CCC23C)C5CC(C)(C)CCC15 FXOCQCYCKZXBIJ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/02—Antioxidant
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Abstract
본 발명은 인동등, 황금, 사삼 및 옥죽 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물에 관한 것이다.
더욱 상세하게는, 인동등 5~10 중량부, 황금 0.5~1.5 중량부, 사삼 0.5~1.5 중량부 및 옥죽 0.5~1.5 중량부로 혼합되며, 에탄올 또는 초산이 3% 함유된 에탄올을 용매로 사용하여 추출되는, 인동등, 황금, 사삼 및 옥죽의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물에 관한 것이다.
본 발명에 따른 조성물은 객담 배출능, 기침 억제능 및 항산화 효능을 보유하고 있다. The present invention relates to a composition for deep sea or dandruff containing an extractive mixture of golden, quartz and jade, as an active ingredient.
More specifically, 5 to 10 parts by weight of potash, 0.5 to 1.5 parts by weight of gold, 0.5 to 1.5 parts by weight of ginseng and 0.5 to 1.5 parts by weight of jade are mixed with ethanol containing 3% of ethanol or acetic acid as a solvent The present invention relates to a composition for a deep sea or a dwarf, which contains, as an active ingredient,
The composition according to the present invention has sputum-releasing ability, cough suppressing ability and antioxidant efficacy.
Description
본 발명은 인동등, 황금, 사삼 및 옥죽 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물에 관한 것이다. The present invention relates to a composition for deep sea or dandruff containing an extractive mixture of golden, quartz and jade, as an active ingredient.
더욱 상세하게는, 인동등 5~10 중량부, 황금 0.5~1.5 중량부, 사삼 0.5~1.5 중량부 및 옥죽 0.5~1.5 중량부로 혼합되며, 에탄올 또는 초산이 0.5~5 % 함유된 에탄올을 용매로 사용하여 추출되는, 인동등, 황금, 사삼 및 옥죽의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물에 관한 것이다. More specifically, 5 to 10 parts by weight of phosphorus, 0.5 to 1.5 parts by weight of gold, 0.5 to 1.5 parts by weight of ginseng and 0.5 to 1.5 parts by weight of jade are mixed with ethanol containing 0.5 to 5% of ethanol or acetic acid as a solvent The present invention also relates to a composition for deep sea or dwarf, which contains, as an active ingredient,
본 발명에 따른 조성물은 객담 배출능, 기침 억제능 및 항산화 효능을 보유하고 있다.
The composition according to the present invention has sputum-releasing ability, cough suppressing ability and antioxidant efficacy.
우리 몸의 호흡기는 물리 화학적인 외부 자극에 대한 방어 기관의 하나로써 급속한 산업화로 인한 대기오염 및 환경변화로 인해 호흡기질환 환자가 급증하고 있다. The respiratory system of our body is one of the defense institutions against the physicochemical external stimuli, and the respiratory disease patients are rapidly increasing due to the air pollution and the environmental change due to the rapid industrialization.
외부 자극물질이 호흡기로 유입되면 일차적으로 코털에 의해 걸러지며, 이를 통과한 미세 자극물질은 점액에 포획되어 섬모 운동을 통해 밖으로 배출되어 진다.
When the external stimulant enters the respiratory tract, it is primarily filtered by the nostrils, and the micro-stimulant that has passed through it is captured by the mucus and released through the ciliary movement.
기침은 점막 자극에 의한 반사적 방어기전으로 지나친 자극이나 지속적인 자극에 의한 지나친 기침은 환자의 삶의 질을 낮추고 기관지의 손상을 가속시킨다.Coughs are caused by mucous membrane stimulation and excessive coughing by excessive irritation or continuous irritation before the reflexive defense mechanism lowers the quality of life of the patient and accelerates the damage of the bronchial tubes.
또한 객담의 경우 외부 유입물질이 타액 또는 점액 물질과 함께 외부로 배출되는데 기관지 염증에 의해 화농성 객담이 발생하게 된다.
In addition, in the case of sputum, exogenous substances are released to the outside together with saliva or mucus material, and purulent sputum is generated by bronchial inflammation.
이러한 증상에 사용되는 의약품 중 진해제로 사용되고 있는 성분은 디하이드로코데인, 메틸에페드린, 클로로페닐라민, 덱스트로메트로판으로 중추신경에 작용하는 것들이다. Among the medicines used for these symptoms, dihydrocodeine, methylphedrine, chlorophenylamine, and dextromethorphan act on the central nervous system.
이러한 성분들은 심혈관계 혈전반응으로 인한 심근경색, 호흡억제, 위 또는 장출혈과 같은 부작용을 나타낸다. These components exhibit side effects such as myocardial infarction, respiratory depression, stomach or intestinal bleeding due to cardiovascular thrombosis.
검담제의 경우 아세틸시스테인, 엘도스테인, 카르보시스테인과 같은 치올계와 암브록솔과 같은 비치올계 거담제가 무분별하게 사용되고 있다.
Chrysanthemums such as acetylcysteine, eldostaine, carbostein, etc., are used indiscriminately in the case of insecticides.
따라서 보다 안전성이 확보된 천연물을 활용하여 진해거담제를 개발하고자 많은 연구가 진행되고 있으며, 본 발명에서는 인동, 황금, 사삼 및 옥죽의 진해/거담 활성을 확인한 결과, 증상을 개선시키는 효능을 확인하여 본 발명을 완성하였다.
Therefore, in the present invention, the activity of improving the symptom is confirmed by confirming the activity of Jinhae / Gadam in the sea bream, gold, quartz and jade, Thereby completing the invention.
인동(忍冬)은 인동과(Caprifoliaceae)에 속하는 인동덩굴(Lonicera Japonica Thunberg)의 잎 및 덩굴성 줄기를 말하며, 인동등(忍冬藤, Lonicera leaf and stem)이라고도 하고, 해열, 해독, 이뇨약으로서 임질, 소변불리, 근골동통 등의 치료약으로 사용되었다.
It is also known as Lonicera leaf and stem. It is also known as Lonicera Japonica Thunberg, which belongs to the genus Caprifoliaceae. , Urine discomfort, and muscle pain.
황금(黃芩)은 꿀풀과에 속한 다년생 초본인 황금(Scutellaria baicalensis Georgi)의 뿌리로써 청열조습(淸熱燥濕), 사화해독(瀉火解毒) 등의 효능이 있다.
Golden (黃 芩) is a perennial plant belonging to the family Lamiaceae ( Scutellaria baicalensis Georgi) has the efficacy as the roots of cheonggyu (淸 热 燥 濕) and poisoning (泻火 解毒).
사삼(沙蔘, Adenophorae Radix)은 초롱꽃과(Campanulaceae)의 잔대(Adenophora triphylla var. japonica Hara 또는 사삼(Adenophora stricta Miq.)의 뿌리이다. Adenophorae Radix is the root of Adenophora triphylla var. Japonica Hara or Adenophora stricta Miq. (Campanulaceae).
사삼의 성분으로 알려진 것은 Taraxerone, Carotene Daucostrol, Octacosanomic acid, phospholipids, phosphatidic acid, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl glycerol, phosphatidyl inositol, Diphosphatidyl glycerol 등이 있다. The known components of the ginseng are Taraxerone, Carotene Daucostrol, Octacosanomic acid, phospholipids, phosphatidic acid, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl glycerol, phosphatidyl inositol and Diphosphatidyl glycerol.
사삼은 전통적으로 진해거담, 기관지염, 천식, 폐렴, 해열, 소변불통에 사용하였다. 최근 연구에 따르면 사삼 물추출물은 항염증 및 천식 억제 효과가 있음이 보고되었다(Roh SS, Kim SH, Lee YC, Seo YB., Mediators Inflamm. 2008).
Sadam has traditionally been used for genital warts, bronchitis, asthma, pneumonia, fever, and urinary incontinence. Recent studies have shown that water extracts from the sea have an anti-inflammatory and anti-asthmatic effect (Roh SS, Kim SH, Lee YC, Seo YB, Mediators Inflamm. 2008).
옥죽(玉竹, Polygonati Odorati Rhizoma)은 백합과(Liliaceae)에 속한 다년생 초본인 둥굴레(Polygonatum odoratum Druce var. pluriflorum Ohwi) 또는 기타 동속 근연식물의 뿌리로써 봄과 가을에 채취하여 건조한 것이다. Polygonati Odorati Rhizoma is a perennial plant belonging to Liliaceae, Polygonatum there is Odoratum Druce. pluriflorum Ohwi) or other related plants in the spring and autumn.
성분으로는 근경에 convallamarin, convallarin, vitamin A 등을 함유하고, 전분 25.6~30.6% 및 점액질을 함유하고 있다. Ingredients include convallamarin, convallarin, and vitamin A in the rhizome, containing 25.6 ~ 30.6% of starch and mucilage.
옥죽은 자양강장효과, 당뇨, 소갈, 허약증상, 영양불량, 폐결핵, 강심작용, 혈압저하, 혈당조절 등에 효능이 있다고 보고되어 있다.
It has been reported that it is effective for the effects of noxious dead nourishment, diabetes, noise, weakness, malnutrition, pulmonary tuberculosis, arteriosclerosis, lowering blood pressure and controlling blood glucose.
한편, 본 발명과 관련된 선행기술로는 등록특허공보 제10-1367803호에 기관지염 치료를 위하여 마황을 포함하는 제약조성물 및 이를 만드는 제조방법에 대하여 기재되어 있다.
On the other hand, as a prior art related to the present invention, Patent Publication No. 10-1367803 discloses a pharmaceutical composition containing mahwang for treating bronchitis and a manufacturing method of the same.
상기 선행기술은 마황, 석고, 연교, 황금, 상백피, 행인, 전호, 반하, 청피, 절패모, 우방자, 금은화, 대황, 길경근 및 감초 등을 포함하고 있으며, 상기 제약조성물은 기침을 완화시키고, 가래를 없애며, 천식을 가라앉히고, 염증을 방지하는 데 유용한 효과가 있다.
The pharmaceutical composition of the present invention is a composition which alleviates coughing and alleviates coughing, and is effective for preventing cough, , Asthma is calmed down, and there is an effect useful in preventing inflammation.
그러나 상기 선행기술은 소재를 각각 추출한 후, 혼합하여 사용하므로 소재의 혼합 추출에 따른 효과를 알 수 없는 문제점이 있다.
However, the prior art has a problem in that the effect of mixed extraction of the material is unknown because the material is extracted and mixed after each extraction.
또한 상기 선행기술은 마황, 연교, 황금, 행인, 반하, 우방자 및 대황은 에탄올 추출하고 있으며, 석고, 상백피, 전호, 청피, 금은화, 길경근 및 감초는 물로만 추출하고 있으므로, 추출용매의 종류에 따른 추출물의 기관지염에 대한 효능은 알 수 없는 문제점이 있다.
In addition, since the above-mentioned prior art extracts ethanol from Mahwang, Kwanghwang, Kwangyang, Golden, passerby, Vanilla, Wisteria and Rhubarb, and extracts only ginseng with gypsum, The efficacy of the extract on bronchitis is unknown.
본 발명과 관련된 또 다른 선행기술로 등록특허공보 제10-0566542호에 알레르기성 비염과 감기의 예방 및 치료용 건강식품조성물 및 그 제조 방법이 기재되어 있다.Another prior art related to the present invention is disclosed in Korean Patent Registration No. 10-0566542, which discloses a health food composition for the prevention and treatment of allergic rhinitis and cold, and a method for producing the same.
상기 선행기술은 유효성분으로 유근피, 진피, 감초, 오미자, 황기, 의이인, 어성초, 삼백초, 계지, 맥문동, 박하, 황금 및 백출을 함유하고 있으며, 재채기, 비즙, 비폐색 등을 포함하는 알레르기 비염의 증상개선에 있어서, 탁월한 치료효과가 있는 것을 특징으로 하고 있다.
The above-mentioned prior arts include symptoms of allergic rhinitis including active ingredients such as rhizomes, dandruff, licorice, omija, hwanggi, It is characterized in that it has an excellent therapeutic effect in improvement.
그러나 상기 선행기술은 알레르기 환자를 대상으로 한 임상 증상만을 관찰하였을 뿐, 입증된 방법을 통하여 실험을 수행하지 않았기 때문에, 조성물의 거담 활성 또는 진해 활성 등에 대한 효능을 객관적으로 평가할 수 없는 문제점이 있다.
However, since the above-described prior art only observes clinical symptoms for allergic patients, it is not possible to objectively evaluate the efficacy of the composition on dandruff activity or vigorous activity, etc., since the experiment was not conducted through the proven method.
또한 상기 선행기술은 열수 추출방법만을 이용하여 추출하고 있기 때문에, 추출용매의 종류에 따른 추출물의 효능은 알 수 없는 문제점이 있다.
In addition, since the prior art is extracted using only the hot water extraction method, there is a problem that the efficacy of the extract according to the type of the extraction solvent is unknown.
본 발명에서 해결하고자 하는 과제는 인동등, 황금, 사삼 및 옥죽 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물을 제공하는 데에 있다.A problem to be solved by the present invention is to provide a composition for deep sea or dandruff containing, as an active ingredient, a mixed extract of gold, quartz and jade, such as indigo.
본 발명에서 해결하고자 하는 과제는 인동등 5~10 중량부, 황금 0.5~1.5 중량부, 사삼 0.5~1.5 중량부 및 옥죽 0.5~1.5 중량부로 혼합되며, 에탄올 또는 초산이 0.5~5 % 함유된 에탄올을 용매로 사용하여 추출되는, 인동등, 황금, 사삼 및 옥죽의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물을 제공하는 데에 있다.A problem to be solved by the present invention is to provide a process for producing an aqueous solution containing 5 to 10 parts by weight of phosphorus, 0.5 to 1.5 parts by weight of gold, 0.5 to 1.5 parts by weight of ginseng and 0.5 to 1.5 parts by weight of corundum, Which comprises extracting a mixture of extracts of indigo, gold, quartz and jade, which are extracted using a solvent as a solvent, as an active ingredient.
본 발명에서 해결하고자 하는 과제는 객담 배출능, 기침 억제능 및 항산화 효능을 보유하는 진해 또는 거담용 조성물을 제공하는 데에 있다.
A problem to be solved by the present invention is to provide a composition for deep sea or dwarf, which has sputum-releasing ability, cough suppressing ability and antioxidant efficacy.
본 발명에서 해결하고자 하는 과제는 인동등, 황금, 사삼 및 옥죽 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물을 제공하는 데에 있다.A problem to be solved by the present invention is to provide a composition for deep sea or dandruff containing, as an active ingredient, a mixed extract of gold, quartz and jade, such as indigo.
본 발명에서 해결하고자 하는 과제는 인동등 5~10 중량부, 황금 0.5~1.5 중량부, 사삼 0.5~1.5 중량부 및 옥죽 0.5~1.5 중량부로 혼합되며, 에탄올 또는 초산이 0.5~5 % 함유된 에탄올을 용매로 사용하여 추출되는, 인동등, 황금, 사삼 및 옥죽의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물을 제공하는 데에 있다.A problem to be solved by the present invention is to provide a process for producing an aqueous solution containing 5 to 10 parts by weight of phosphorus, 0.5 to 1.5 parts by weight of gold, 0.5 to 1.5 parts by weight of ginseng and 0.5 to 1.5 parts by weight of corundum, Which comprises extracting a mixture of extracts of indigo, gold, quartz and jade, which are extracted using a solvent as a solvent, as an active ingredient.
본 발명에서 해결하고자 하는 과제는 객담 배출능, 기침 억제능 및 항산화 효능을 보유하는 진해 또는 거담용 조성물을 제공하는 데에 있다.
A problem to be solved by the present invention is to provide a composition for deep sea or dwarf, which has sputum-releasing ability, cough suppressing ability and antioxidant efficacy.
본 발명에 따른 인동등, 황금, 사삼 및 옥죽의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물은 객담 배출능이 뛰어난 효능을 보유하고 있다.The composition for deep sea or dandruff containing the mixed extract of gold, quartz and jade, as the active ingredient, according to the present invention has excellent efficacy on sputum emission.
본 발명에 따른 인동등, 황금, 사삼 및 옥죽의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물은 기침 억제능이 뛰어난 효능을 보유하고 있다.The composition for deep sea or dandruff containing the mixed extract of gold, quartz and jade, as an effective ingredient, according to the present invention has an excellent effect of inhibiting cough.
본 발명에 따른 인동등, 황금, 사삼 및 옥죽의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물은 항산화 활성이 뛰어난 효능을 보유하고 있다.
The composition for deep sea or dandruff containing the mixed extract of gold, quartz and jade, as an effective ingredient, according to the present invention has an excellent antioxidant activity.
도 1은 혼합 추출물의 객담 배출능을 나타낸 것으로, 배출된 페놀의 농도를 측정한 그래프이다.
도 2는 혼합 추출물의 기침 억제능을 나타낸 것으로, 5초 동안 발생한 기침횟수를 측정한 그래프이다.
도 3은 혼합 추출물들의 항산화 효과를 나타낸 그래프로서, 흡광도를 %로 환산하여 나타낸 그래프이다. FIG. 1 shows the sputum-releasing activity of the mixed extract, which is a graph measuring the concentration of the released phenol.
FIG. 2 is a graph showing the cough suppressing ability of the mixed extract, which is a measurement of the number of coughs occurring for 5 seconds.
FIG. 3 is a graph showing the antioxidative effect of the mixed extracts, and is a graph showing the absorbance in terms of%.
본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 안 되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.
The terms and words used in the present specification and claims should not be construed as limited to ordinary or dictionary terms and the inventor may properly define the concept of the term in order to best describe its invention It should be construed as meaning and concept consistent with the technical idea of the present invention.
따라서 본 명세서에 기재된 실험예와 참고예는 본 발명의 가장 바람직한 일실시예에 불과한 뿐이고 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형예들이 있을 수 있음을 이해하여야 한다.
Therefore, the experimental examples and the reference examples described in the present specification are merely the most preferred embodiments of the present invention and are not intended to represent all of the technical ideas of the present invention. Therefore, various equivalents and variations Examples should be understood.
실시예Example
1. One.
인동등Incandescent light
, 황금, , Gold,
사삼Sasayam
및 And
옥죽Jade
혼합 추출물( Mixed extract (
HAEHAE
-05)의 제조-05)
인동등, 황금, 사삼 및 옥죽은 5~10 : 0.5~1.5 : 0.5~1.5 : 0.5~1.5 중량부로 혼합되어 추출될 수 있다. 바람직하게는 7~9 : 1 : 1 : 1의 중량부로 혼합하여 사용할 수 있다.
5 to 10: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5 parts by weight of gold, silver and rhododendrons. Preferably 7 to 9: 1: 1: 1.
추출 방법은 이산화탄소 초임계 추출법, 수증기 증류법, 진공추출법, 감압추출법, 마이크로 웨이브 공정 추출법, 퍼콜레이션 추출법 등의 다양한 추출 방법이 사용될 수 있으나, 바람직하게는 용매 추출법이 사용될 수 있다.
Various extraction methods such as a carbon dioxide supercritical extraction method, a steam distillation method, a vacuum extraction method, a vacuum extraction method, a microwave process extraction method, and a percolation extraction method may be used, but a solvent extraction method may be preferably used.
추출에 사용되는 용매는 물, 에탄올, 메탄올, 지방유, 글리세린, 마유, 플로필렌글리콜, 에테르, 클로르포름, 석유에테르, 헥산, 벤젠, 메틸렌클로라이드, 에틸아세테이트, 아세톤, 부탄올, 이소프로판올, 액체암모니아, 삼염화안티몬 및 불화수소 등에서 선택될 수 있다.
The solvent used for the extraction is selected from the group consisting of water, ethanol, methanol, fatty oil, glycerin, hemp, flouropylene glycol, ether, chloroform, petroleum ether, hexane, benzene, methylene chloride, ethyl acetate, acetone, butanol, isopropanol, Antimony, hydrogen fluoride and the like.
바람직한 추출방법으로는 소재를 혼합한 후, 30%(v/v) 에탄올 수용액을 10배수 넣고 80~90℃로 3시간 환류냉각 추출한 후 여과하여 1차 추출액을 얻을 수 있다.
As a preferred extraction method, the materials are mixed, and then 10% aqueous solution of 30% (v / v) ethanol is added thereto, refluxed at 80 to 90 ° C for 3 hours and then filtered to obtain a primary extract.
잔사를 1차 추출방법과 동일하게 반복 추출한 다음 추출액을 60℃ 이하에서 감압농축 하고 진공건조 하여 건조엑스를 얻음으로써, 인동등, 황금, 사삼 및 옥죽 혼합 추출물을 제조할 수 있다.
The residue is repeatedly extracted in the same manner as in the first extraction method, and then the extract is concentrated under reduced pressure at 60 ° C or lower and vacuum dried to obtain dried extract to produce a mixture of golden, quartz and jade mixed extracts.
실시예Example
2. 2.
인동등Incandescent light
, 황금, , Gold,
사삼Sasayam
및 And
옥죽Jade
혼합 추출물( Mixed extract (
HAEHAE
-06)의 제조-06)
실시예 1에 따른 방법과 동일하게 수행하되, 추출 용매를 30%(v/v) 에탄올 수용액에서, 3%(v/v) 초산이 포함된 30%(v/v) 에탄올 수용액으로 변경하여 추출한다.
(V / v) aqueous solution of ethanol containing 3% (v / v) acetic acid in 30% (v / v) do.
실시예 1 및 2에 따른 인동등, 황금, 사삼 및 옥죽 혼합 추출물의 효능을 평가하기 위해, 인동등, 황금 및 길경 혼합 추출물을 제조하여 함께 비교하였다.
In order to evaluate the efficacy of the mixed extracts of golden, quartz and jade, according to Examples 1 and 2, mixed extracts of golden and Gyungyang were prepared and compared together.
비교예Comparative Example
1. One.
인동등Incandescent light
, 황금 및 , Gold and
길경Gakyung
혼합 추출물( Mixed extract (
HAEHAE
-01)의 제조 -01)
인동등 120 g, 황금 40 g, 길경 40 g을 넣고 30%(v/v) 에탄올 수용액을 10배수 넣고 80~90℃로 3시간 환류냉각 추출한 후 여과하여 1차 추출액을 얻는다. 40 g of gold and 40 g of gypsum and put in 10 volume of 30% (v / v) ethanol solution, reflux cooled for 3 hours at 80 ~ 90 ℃ and then filtered to obtain a primary extract.
잔사를 1차 추출방법과 동일하게 반복 추출한 다음 추출액을 60℃ 이하에서 감압농축 하고 진공건조 하여 건조엑스 약 57.6 g(수율 28.80%)을 얻는다.
The residue is repeatedly extracted in the same manner as in the first extraction method. The extract is concentrated under reduced pressure at 60 ° C or lower and vacuum dried to obtain about 57.6 g (yield: 28.80%) of dried extract.
비교예Comparative Example
2. 2.
인동등Incandescent light
, 황금 및 , Gold and
길경Gakyung
혼합 추출물( Mixed extract (
HAEHAE
-02)의 제조-02)
인동등 120 g, 황금 40 g, 길경 40 g을 넣고 3%(v/v) 초산이 포함된 30%(v/v) 에탄올 수용액을 10배수 넣고 80~90℃로 3시간 환류냉각 추출한 후 여과하여 1차 추출액을 얻는다. (V / v) aqueous ethanol solution containing 3% (v / v) acetic acid was added to 10 g of water, reflux cooled for 3 hours at 80 to 90 ° C., To obtain a primary extract.
잔사를 1차 추출방법과 동일하게 반복 추출한 다음 추출액을 60℃ 이하에서 감압농축 하고 진공건조 하여 건조엑스 약 53.5 g(수율 26.75%)을 얻는다.
The residue is repeatedly extracted in the same manner as in the first extraction method. The extract is concentrated under reduced pressure at 60 ° C or lower and vacuum dried to obtain about 53.5 g (yield: 26.75%) of dried extract.
실험예Experimental Example
1. 거담 활성 평가 1. Evaluation of gadam activity
1-1. 실험 과정1-1. Experimental course
제조된 혼합 추출물의 거담 활성을 평가하기 위하여, Engler 등의 방법을 이용하여(Engler H, Szelenyi I, J.Pharmacol. Moth.11,151~157,1984., Bao-quin Lin et., Pulmonary Pharmacology & Therapeutics 21, 259~263, 2008.) 평가 실험을 수행하였다. 실험과정은 다음과 같다.
(Engler H, Szelenyi I, J. Pharmacol. Moth., 151 ~ 157, 1984, Bao-quin Lin et al., Pulmonary Pharmacology & Therapeutics 21, 259-263, 2008.) Evaluation experiments were conducted. The experimental procedure is as follows.
① 양성대조약물(암브록솔, ambroxol, Sigma), 시험약물을 수컷랫트(6주령, 샘타코 바이오코리아)에 경구 투여하고 30분 후, 페놀레드를 복강주사 하였다(200 mg/kg 용량으로 투여하며, 페놀레드는 생리식염수에 녹여서 사용함). The test compound was orally administered to male rats (6 weeks old, Sumatoco Bio Korea) for 30 minutes, and the test compound was intraperitoneally injected with phenol red (200 mg / kg dose) And phenol red dissolved in physiological saline).
② 30분 후 디에틸에테르를 이용해 마취시키고 복부 대동맥을 절단하여 방혈시킨 후, 기관 (trachea) 전체를 절제하였다. ② After 30 minutes, anesthesia was performed with diethyl ether, and the abdominal aorta was cut to bleed, and then the entire trachea was excised.
③ 분리된 기관을 1 ml의 생리 식염수에 넣어 30 분 동안 세척하였고, 10,000 rpm으로 5분간 상온에서 원심분리하여 얻은 상등액에 1 N 가성소다 (NaOH)를 첨가 (상등액 1 ml당 1N NaOH 0.1 ml 첨가)하였다. ③ Separated organs were washed with 1 ml of physiological saline solution for 30 minutes and centrifuged at 10,000 rpm for 5 minutes at room temperature. 1 N sodium hydroxide (NaOH) was added (0.1 ml of 1N NaOH per 1 ml of supernatant ).
④ 이들에 대한 546 nm에서의 흡광도를 측정하여 배출된 페놀레드의 농도로서 거담활성을 평가하였다.
(4) The absorbance at 546 nm was measured to evaluate the drought activity as the concentration of the phenol red discharged.
1-2. 실험 결과1-2. Experiment result
아래 [표 1]은 양성대조약물로 사용된 암브록솔과 제조된 혼합 추출물의 투여 용량에 따른 객담 배출능을 나타낸 표이다.
Table 1 below is a table showing the sputum-releasing ability according to the administration dose of ambroxol used as a positive control drug and the mixed extract prepared.
실험 결과, 인동등, 황금 및 길경 에탄올 추출물(HAE-01)에 비해 인동등, 황금, 사삼 및 옥죽 에탄올 추출물(HAE-05)의 객담 배출능이 높은 것을 알 수 있으며, 인동등, 황금 및 길경의 초산 3% 함유 에탄올 추출물(HAE-02)에 비해, 인동등, 황금, 사삼 및 옥죽의 초산 3% 에탄올 추출물(HAE-06)의 객담 배출능이 높은 것을 알 수 있다.
As a result, it was found that the sputum-producing ability of ethanol extract (HAE-05) of golden, quartz, and japonica was higher than that of golden and Gyungyang ethanol extracts (HAE-01) The ethanol extract (HAE-06) of 3% acetic acid in gold, silver and manganese, etc., has a higher sputum emission ability than ethanol extract (HAE-02) containing 3% acetic acid.
따라서 동일한 방법과 용매로 추출하였지만, 인동등, 황금 및 길경 조합보다는 인동등, 황금, 사삼 및 옥죽 조합의 추출물이 객담 배출능이 더욱 뛰어난 것을 알 수 있다. Therefore, it was found that the extracts of golden, quartz, and kokkuk extracts were more excellent in the sputum-releasing ability than the iron and the gold and Gyokyung combinations, although they were extracted by the same method and solvent.
또한 에탄올 추출물보다는 초산 3%가 함유된 에탄올 추출물의 객담 배출능이 더 뛰어난 것을 확인하였다.
In addition, ethanol extracts containing 3% acetic acid showed better sputum emission than ethanol extracts.
특히 HAE-06 실험군의 경우, 투여용량을 환산하여 비교하면 양성대조군으로 사용된 암브록솔의 객담 배출능보다 더 뛰어난 효능을 보유하는 것을 알 수 있다.
In particular, HAE-06 experimental group has higher efficacy than spleen-releasing ability of ambroxol used as positive control in comparison with dose.
도 1은 혼합 추출물의 객담 배출능을 나타낸 것으로, 배출된 페놀의 농도를 측정한 그래프이다.
FIG. 1 shows the sputum-releasing activity of the mixed extract, which is a graph measuring the concentration of the released phenol.
실험 결과, 대조군에 비해 양성대조군인 암브록솔의 페놀 농도가 약 2배가량 증가한 것을 확인할 수 있다. As a result, it was confirmed that the concentration of amoxicillin phenol in the positive control group was about twice that of the control group.
HAE-01, 02, 05 및 06 실험군은 모두 대조군에 비해 페놀 농도가 증가한 것을 보여, 객담 배출능을 보유하고 있음을 알 수 있다.
The HAE-01, 02, 05, and 06 experimental groups showed an increase in phenol concentration compared with the control group, indicating that they had sputum-releasing ability.
특히 인동등, 황금, 사삼 및 옥죽의 혼합 추출물(HAE-05 및 HAE-06)은 인동등, 황금 및 길경 혼합 추출물에 비해 유의한 객담 배출능을 보이는 것을 확인하였다.
(HAE-05 and HAE-06) showed significant sputum-releasing ability compared to the extracts of golden and Gyungyang mixed extracts.
실험예Experimental Example
2. 진해 활성 평가 2. Evaluation of Chinhae activity
2-1. 실험 과정2-1. Experimental course
혼합 추출물에 대하여 진해 활성을 측정하기 위해, Tanaka 등의 방법을 이용하여(Motomu Tanaka and Kei Maruyama., J. Pharmacol.Sci. 93, 465~470, 2003., Daoui, Cognon, Naline et., Am. J. Respir. Crit. Care. Med. 158, 42~48, 1998.)평가하였다. 실험과정은 다음과 같다.
In order to measure the activity of the mixed extract, Tanaka et al. (Motomu Tanaka and Kei Maruyama, J. Pharmacol. Sci., 93, 465-470, 2003. Daoui, Cognon, Naline et. J. Respir. Crit Care, Med., 158, 42-48, 1998.). The experimental procedure is as follows.
① 수컷 ICR 마우스(6주령, 오리엔트바이오)에 약물을 경구투여하고 30분후 마우스를 플레티시스모그래프 챔버 (Buxco, U.S.A.)에 넣은 후, 기침 유발제 (시트르산)를 분무하여 기침을 유발시켰다.After 30 minutes of oral administration of the drug to a male ICR mouse (6 weeks old, Orient Bio), the mice were placed in a plexi-smear chamber (Buxco, USA) and cough induced by spraying a cough inducer (citric acid).
② 양성대조군으로는 진해제로 사용되고 있는 테오브로민(50 mg/kg)을 사용하였으며, 0.4 M의 시트르산에 마우스를 10분간 노출시키고 이때 발생하는 기침수를 5초 간격으로 10분간 측정하였다.
Theobromine (50 mg / kg) was used as a positive control, and mice were exposed to 0.4 M citric acid for 10 minutes, and the cough water generated was measured at intervals of 5 seconds for 10 minutes.
2-2. 실험 결과2-2. Experiment result
아래 [표 2]는 양성대조약물로 사용된 테오브로민과 제조된 혼합 추출물의 투여 용량에 따른 기침 억제능을 나타낸 표이다.
Table 2 below is a table showing cough inhibition according to the dose of theobromine used as a positive control drug and the mixed extract prepared.
실험 결과, HAE-06 실험군의 기침횟수가 2.04 ± 0.33으로 가장 낮으며, 이는 양성대조약물인 테오브로민을 처리한 실험군의 2.31 ± 0.17보다 낮은 것을 알 수 있다.
As a result, the number of coughs in the HAE-06 group was the lowest at 2.04 ± 0.33, which is lower than that of the group treated with theobromine, the positive control, 2.31 ± 0.17.
도 2는 혼합 추출물의 기침 억제능을 나타낸 것으로, 5초 동안 발생한 기침횟수를 측정한 그래프이다.
FIG. 2 is a graph showing the cough suppressing ability of the mixed extract, which is a measurement of the number of coughs occurring for 5 seconds.
도 2에서 보는 바와 같이, 대조군에 비해 테오브로민 처리군에서 기침횟수가 감소하는 것을 확인하였다. As shown in FIG. 2, the number of coughs decreased in the theobromine-treated group compared to the control group.
또한 HAE-06의 기침횟수가 가장 감소한 것을 확인하여, 인동등, 황금, 사삼 및 옥죽의 초산 3% 에탄올 추출물의 기침 억제능이 더 뛰어난 것을 확인하였다.
In addition, it was confirmed that the coughing frequency of HAE-06 was the lowest, and it was confirmed that the 3% ethanolic extract of acetic acid of gold,
실험예Experimental Example
3. 항산화 활성 평가 3. Antioxidant activity evaluation
3-1. 실험 과정3-1. Experimental course
DPPH assay는 항산화 효능을 측정하는 실험 중 가장 보편적인 실험 중 하나이다. DPPH assay의 원리는 진한 보라색을 띠는 Diphenylpicrylhydrazyl이 항산화제에 의해 Diphenylpicrylhydrazine으로 환원되어 옅은 노란색으로 변하는 것으로, 항산화제의 항산화력이 강할 수록 옅은 노란색에 가까워진다.The DPPH assay is one of the most common experiments to measure antioxidant efficacy. The principle of DPPH assay is that the deep purple Diphenylpicrylhydrazyl is reduced to Diphenylpicrylhydrazine by the antioxidant and turns into a pale yellow. The stronger the antioxidant power of the antioxidant, the closer to the pale yellow.
또한 흡광도 측정시 짙은 보라색은 감지되나 옅은 노란색은 감지되지 못한다. 따라서 흡광도의 수치가 작게 나올수록 항산화력이 높은 것이라고 할 수 있다. 실험 과정은 다음과 같다.
Also, when measuring the absorbance, a dark purple color is detected but a light yellow color is not detected. Therefore, the smaller the absorbance value is, the higher the antioxidant power is. The experimental procedure is as follows.
① 0.1 mM DPPH 용액(Diphenylpicrylhydrazyl)을 8그룹 준비하였다. ① 8 groups of 0.1 mM DPPH solution (Diphenylpicrylhydrazyl) were prepared.
② 1 그룹은 음성 대조군으로 설정하여 어떤 조작도 하지 않았으며, 2그룹은 양성 대조군으로 설정하여 ascorbic acid(Vitamin C) 50 M을 처리하였다. ② Group 1 was set as negative control and no manipulation was performed.
③ 실험 그룹에는 추출물을 각각 10 g/mL, 30g/mL, 100 g/mL씩 처리하였다. ③ In the experiment group, the extracts were treated with 10 g / mL, 30 g / mL and 100 g / mL, respectively.
④ 520nm의 파장에서 흡광계를 이용하여 시료들의 색이 어떻게 변하는지 관찰하였다.④ We observed how the color of the samples changed using a light absorber at a wavelength of 520 nm.
⑤ 측정된 흡광도를 다음의 식으로 %환산하였다.
⑤ The measured absorbance was converted in% by the following equation.
3-2. 실험 결과3-2. Experiment result
다음 [표 3]은 혼합 추출물의 항산화 효능을 나타낸 것으로, 처리용량에 따른 항산화 효과를 나타낸 표이며, 도 3은 혼합 추출물들의 항산화 효과를 나타낸 그래프로서, 흡광도를 %로 환산하여 나타낸 그래프이다.
The following Table 3 shows the antioxidative effect of the mixed extracts. The antioxidative effect of the mixed extracts is shown in Table 3, and FIG. 3 is a graph showing the antioxidative effect of the mixed extracts.
HAE-01
HAE-01
HAE-02
HAE-02
HAE-05
HAE-05
HAE-06
HAE-06
실험 결과, 모든 실험군에서 항산화 활성이 나타났으며, 농도의존적으로 증가하였다. 그러나, 30 ㎍/㎖ 처리군에 비해, 100 ㎍/㎖ 처리군의 항산화 활성이 약간 감소하는 것을 확인하였다.
As a result, antioxidant activity was observed in all experimental groups and increased in concentration dependent manner. However, it was confirmed that the antioxidative activity of the 100 ㎍ / ㎖ treated group was slightly reduced compared to the 30 ㎍ / ㎖ treated group.
30 ㎍/㎖ 처리시 혼합 추출물의 항산화 활성은 양성대조군인 ascorbic acid(Vitamin C)와 유사한 수준의 항산화 활성을 보였다. At 30 ㎍ / ㎖ treatment, the antioxidant activity of the mixed extracts showed similar antioxidative activity to ascorbic acid (Vitamin C), which is a positive control.
Claims (5)
상기 혼합 추출물은, 인동등 5~10 중량부, 황금 0.5~1.5 중량부, 사삼 0.5~1.5 중량부 및 옥죽 0.5~1.5 중량부로 혼합되고,
에탄올 또는 초산이 0.5~5 % 함유된 에탄올을 용매로 사용하여 추출되며,
객담 배출능, 기침 억제능 및 항산화 효능을 보유하는 것을 특징으로 하는, 인동등, 황금, 사삼 및 옥죽의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 약학 조성물.
Ginseng, and rhubarb, and a mixture of gold,
The mixed extract is mixed with 5 to 10 parts by weight of potash, 0.5 to 1.5 parts by weight of gold, 0.5 to 1.5 parts by weight of ginseng and 0.5 to 1.5 parts by weight of jade,
Extracted with ethanol containing 0.5 to 5% of ethanol or acetic acid as a solvent,
A pharmaceutical composition for chewing gum or dandruff comprising an extract of Huangdong, gold, quartz and jade, as an active ingredient, characterized by having sputum-releasing ability, cough suppressing ability and antioxidant efficacy.
상기 혼합 추출물은, 인동등 5~10 중량부, 황금 0.5~1.5 중량부, 사삼 0.5~1.5 중량부 및 옥죽 0.5~1.5 중량부로 혼합되고,
에탄올 또는 초산이 0.5~5 % 함유된 에탄올을 용매로 사용하여 추출되며,
객담 배출능, 기침 억제능 및 항산화 효능을 보유하는 것을 특징으로 하는, 인동등, 황금, 사삼 및 옥죽의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 건강기능식품 조성물.Ginseng, and rhubarb, and a mixture of gold,
The mixed extract is mixed with 5 to 10 parts by weight of potash, 0.5 to 1.5 parts by weight of gold, 0.5 to 1.5 parts by weight of ginseng and 0.5 to 1.5 parts by weight of jade,
Extracted with ethanol containing 0.5 to 5% of ethanol or acetic acid as a solvent,
Wherein the composition has a sputum-releasing ability, a cough suppressing ability, and an antioxidant activity as an effective ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140140787A KR101619733B1 (en) | 2014-10-17 | 2014-10-17 | A composition for anti-tussive activity or discharge of phlegm activity comprising of lonicera japonica, scutellaria baicalensis, adenophorea radix and polygonati odorati |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140140787A KR101619733B1 (en) | 2014-10-17 | 2014-10-17 | A composition for anti-tussive activity or discharge of phlegm activity comprising of lonicera japonica, scutellaria baicalensis, adenophorea radix and polygonati odorati |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20160045368A KR20160045368A (en) | 2016-04-27 |
KR101619733B1 true KR101619733B1 (en) | 2016-05-12 |
Family
ID=55914662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140140787A KR101619733B1 (en) | 2014-10-17 | 2014-10-17 | A composition for anti-tussive activity or discharge of phlegm activity comprising of lonicera japonica, scutellaria baicalensis, adenophorea radix and polygonati odorati |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101619733B1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11129861B2 (en) | 2017-02-01 | 2021-09-28 | Okchundang Co., Ltd. | Methods for treating inflammatory diseases |
KR102022325B1 (en) | 2017-02-01 | 2019-09-18 | (주)옥천당 | Compositions for Antitussive, Expectorant or Anti-inflammation |
KR20190109220A (en) | 2018-03-16 | 2019-09-25 | 주식회사 헬릭스미스 | Herbal Composition for Preventing or Treating Respiratory Disease |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102526467A (en) * | 2012-02-15 | 2012-07-04 | 中国人民解放军第三军医大学第二附属医院 | Chinese medicinal composition for treating pulmonary fungal infection and preparation method thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100566542B1 (en) | 2004-04-20 | 2006-03-30 | (주)바이오솔루션 | A health food composition for prevention and treatment of allergic rhinitis and influenza and a method for preparation thereof |
KR101367803B1 (en) | 2012-09-18 | 2014-02-28 | 굿스틸뱅크 주식회사 | Heater of metal fiber manufacturing apparatus |
-
2014
- 2014-10-17 KR KR1020140140787A patent/KR101619733B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102526467A (en) * | 2012-02-15 | 2012-07-04 | 中国人民解放军第三军医大学第二附属医院 | Chinese medicinal composition for treating pulmonary fungal infection and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20160045368A (en) | 2016-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006123950A (en) | METHODS FOR TREATING PROSTANT CANCER WITH HERBAL COMPOSITIONS | |
KR101103393B1 (en) | Composition containing a herbal extract for preventing and treating respiratory organ disease | |
KR101346244B1 (en) | Composition for preventing or relieving alcohol-induced hangover comprising medicinal herbs | |
Fierascu et al. | Leonurus cardiaca L. as a source of bioactive compounds: an update of the European medicines agency assessment report (2010) | |
KR100970739B1 (en) | Composition comprising the extract of Coptidis Rhizoma for preventing and treating respiratory organ disease | |
KR101619733B1 (en) | A composition for anti-tussive activity or discharge of phlegm activity comprising of lonicera japonica, scutellaria baicalensis, adenophorea radix and polygonati odorati | |
KR101286467B1 (en) | A composition comprising mixed herbal extract of Cnidii Rhizoma and Undulatum Rhubarb for treating or preventing respiratory disease | |
US20140030368A1 (en) | Composition for preventing or treating a respiratory disease containing a mixed herbal extract of cnidium officinale root and polygoni cuspidati root | |
JP6712056B2 (en) | Hepatocyte growth factor production inducer | |
KR101286463B1 (en) | A composition comprising extract of Cnidii Rhizoma for treating or preventing respiratory disease | |
KR101732720B1 (en) | A composition for anti-tussive activity or discharge of phlegm activity comprising of lonicera japonica, scutellaria baicalensis and liriopis tuber | |
KR101286465B1 (en) | A composition comprising mixed herbal extract of Cnidii Rhizoma and Corydalis Tuber for treating or preventing respiratory disease | |
CN110742939B (en) | Preparation of traditional Chinese medicine compound composition and application thereof in treating upper respiratory tract infection | |
JP6302425B2 (en) | Antiviral agent | |
JP7407735B2 (en) | A composition having antitussive and expectorant activity, comprising extracts of Schisandra and Schisandra | |
Akhil | A pharmacological evaluation for the ethanolic extract of Alpinia Calcarata rhizome for it’s anti-asthmatic, antioxidant and anti-inflammatory activities | |
CN103655586B (en) | Medicagenic acid-3-O-β-D-Glucose glycosides prevents and treats the application in osteopathia medicine in preparation | |
CN103705599B (en) | A kind of pharmaceutical composition for the treatment of cough and preparation method thereof | |
KR101086258B1 (en) | Preventive and curative extracts from medicinal plants and their composition for respiratory organ disease | |
CN115645486A (en) | Traditional Chinese medicine composition for clearing heat and reducing internal heat and preparation method thereof | |
Singh | Ayurvedic Rasayana Guduchi (Tinospora cordifolia): A Review | |
Bharathi et al. | Cassia alata: phytopharmacological, traditional, and medicinal considerations | |
CN113876878A (en) | Herbal formula for promoting production of body fluid and relieving cough and preparation method | |
KR20230047320A (en) | Composition for treating alzheimer's disease comprising the extract of Pinelliae Tuber, Jujube, Glycyrrhiza uralensis, Ginseng Radix, Zingiberis Rhizoma, Scutellaria baicalensis, and Coptis chinensis as an effective component | |
KR101086256B1 (en) | Preventive and curative extracts from Gentianae macrophyllae radix for respiratory organ disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20190514 Year of fee payment: 4 |